Unlike generic multivitamins or standalone supplements, Replenza positions itself as a targeted system designed to address the specific nutritional gaps that GLP-1 users face
The medication is not FDA-approved yet and is currently in phase 3 clinical trials
While CGM data is often siloed, linking it with Truvetas rich clinical data allows for more comprehensive studies on the combined effects of GLP-1s and CGMs on glycemic control, treatment adherence, and overall patient outcomes
Questions We Get Asked Straight answers on batch proof, storage, dispatch, and support
Someone could use tirzepatide during the active weight loss phase, achieving the maximum possible weight reduction with the dual-receptor mechanism, and then transition to orforglipron for long-term maintenance
If you like what you read and want it in your inbox, sign up here